CYTOKINETICS, INCORPORATED Fair Value of Long-Term Debt
CYTOKINETICS, INCORPORATED (CYTK) had Fair Value of Long-Term Debt of $47.40 million as of 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Notes › Debt
us-gaap:LongTermDebtFairValue · last filed 2022-02-25
- 2021-12-31: Long-term Debt, Fair Value $47.40M.
- 2021-09-30: Long-term Debt, Fair Value $47.10M.
- 2021-06-30: Long-term Debt, Fair Value $46.80M.
- 2021-03-31: Long-term Debt, Fair Value $46.50M.
| Period end | Long-term Debt, Fair Value | Long-term Debt, Fair Value as first filed |
|---|---|---|
| 2021-12-31 | $47.40M 10-K · filed 2022-02-25 | |
| 2021-09-30 | $47.10M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $46.80M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $46.50M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $46.20M 10-K · filed 2021-02-26 | |
| 2020-09-30 | $45.90M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $45.60M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $45.30M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $45.10M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $44.80M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $44.50M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $42.60M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $42.40M 10-K · filed 2020-03-04 | $42.10M 10-K · filed 2019-03-07 |
| 2018-09-30 | $41.90M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $32.40M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $32.00M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $31.80M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $30.30M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $30.00M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $30.00M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $29.90M 10-K · filed 2018-03-05 | |
| 2016-03-31 | $29.50M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $14.60M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $0.00 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |